NASDAQ:CPRXCatalyst Pharmaceuticals Stock Price, Forecast & News

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CPRX shares have increased by 42.3% and is now trading at $5.01. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) posted its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The biopharmaceutical company earned $29.14 million during the quarter, compared to analyst estimates of $31.68 million. Catalyst Pharmaceuticals had a net margin of 36.09% and a return on equity of 52.28%. View Catalyst Pharmaceuticals' earnings history.

4 Wall Street analysts have issued 1 year target prices for Catalyst Pharmaceuticals' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 89.6% from the stock's current price. View analysts' price targets for Catalyst Pharmaceuticals.

News headlines about CPRX stock have been trending positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news about Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 13,890,000 shares, an increase of 8.5% from the June 15th total of 12,800,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the short-interest ratio is currently 7.2 days. Currently, 14.4% of the shares of the stock are sold short. View Catalyst Pharmaceuticals' Current Options Chain.

Some companies that are related to Catalyst Pharmaceuticals include Principia Biopharma (PRNB), IGM Biosciences (IGMS), Prestige Consumer Healthcare (PBH), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), I-Mab (IMAB), Dicerna Pharmaceuticals (DRNA), Ironwood Pharmaceuticals (IRWD), Cytokinetics (CYTK), Aurinia Pharmaceuticals (AUPH), Myovant Sciences (MYOV) and Madrigal Pharmaceuticals (MDGL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), SCYNEXIS (SCYX) and Micron Technology (MU).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.12%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Gary Ingenito and Patrick J Mcenany. View institutional ownership trends for Catalyst Pharmaceuticals.

CPRX stock was acquired by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, and Patrick J Mcenany. View insider buying and selling activity for Catalyst Pharmaceuticals.

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CPRX stock can currently be purchased for approximately $5.01.

Catalyst Pharmaceuticals has a market capitalization of $518.13 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]